New combo therapy aims to tackle tough pancreatic cancer
NCT ID NCT03983057
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed phase 2 trial tested whether adding an anti-PD-1 immunotherapy drug to standard chemotherapy (modified-FOLFIRINOX) helps patients with locally advanced or borderline resectable pancreatic cancer. The study enrolled 392 participants and compared the combination against chemotherapy alone. The goal was to see if the combo improves event-free survival, overall survival, and tumor shrinkage rates.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Anti-PD-1 antibody (immunotherapy) combined with modified-FOLFIRINOX chemotherapy
- What this could lead to
- If successful, this combination could improve tumor shrinkage and delay progression in patients with pancreatic cancer that hasn't spread, potentially making more tumors operable.
- What could go wrong
- This is a phase 2 trial, so results are still early. The added immunotherapy may increase side effects without guaranteeing better survival, and not all patients may respond.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
the First Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310003, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pancreatic Cancer's inflammatory footprint be stopped?
- Could a vaccine help fight Hard-to-Treat cancers?
- Blood and gut clues may flag pancreatic cancer risk early
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- MRI might reveal hidden pancreatic risks in obesity
- Can a new drug combo shrink Hard-to-Treat tumors?